Our Pipeline

Building a pipeline to bring the promise of cell therapies to more patients

Clinical Trials

CHM 1101 (CLTX CAR T) PHASE 1B MULTI-SITE CLINICAL TRIAL

Phase 1b, multicenter, feasibility/safety study of CHM 1101 in participants with recurrent or progressive GBM.

Phase 1B

CLINICAL TRIAL IN recurrent/ progressive GLIOBLASTOMA

Clinical Trials – CHM 0201

Investigator initiated Phase 1B clinical trials to explore CHM 0201 combination therapies.

Abstracts and Publications

November 2021

Clinical Evaluation of Chlorotoxin-Directed CAR T Cells for Patients With Recurrent Glioblastoma

November 2021

Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognize glioblastoma cells?

November 2021

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells

August 2021

A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells Incorporating a Chlorotoxin Tumor-targeting Domain for Patients with MMP2+ Recurrent or Progressive Glioblastoma

Click on the icons below to download preferred medium


MP4 15MB	PowerPoint 3.5 MB	PDF 0.5 MB

March 2020

Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma

November 2019

Current Biochemical Applications and Future Prospects of Chlorotoxin in Cancer Diagnostics and Therapeutics

November 2016

Glioblastoma multiforme targeted therapy: The Chlorotoxin story

August 2002

Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin